Publications
Publications
Show Results For
- All HBS Web
(1,552)
- Faculty Publications (402)
- June 2003 (Revised May 2006)
- Case
Cipla
By: Rohit Deshpande and Laura Winig
The head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line... View Details
- March 2003
- Article
Technological Development and Medical Productivity: The Diffusion of Angioplasty in New York State
By: David M. Cutler and Robert S. Huckman
A puzzling feature of many medical innovations is that they simultaneously appear to reduce unit costs and increase total costs. We consider this phenomenon by examining the diffusion of percutaneous transluminal coronary angioplasty (PTCA)—a treatment for coronary... View Details
- October 2002 (Revised March 2013)
- Case
Intermountain Health Care
By: Richard M.J. Bohmer, Amy C. Edmondson and Laura Feldman
Intermountain Health Care (IHC), an integrated delivery system based in Utah, has adopted a new strategy for managing health care delivery. The approach focuses management attention not only on the facilities where care takes place but also on physician decision making... View Details
- August 2002 (Revised August 2002)
- Case
Raiser Senior Services--The Stratford (A)
By: H. Kent Bowen and Alison Berkley Wagonfeld
Focuses on modifying operations to increase profitability at an upscale senior care facility in California. Jennifer Raiser, president of Raiser Senior Services, opened the Stratford in 1992 as a high-end, continuing-care retirement community. Ten years later, the... View Details
- 2002
- Book
Searching for a Corporate Savior: The Irrational Quest for Charismatic CEOs
By: Rakesh Khurana
Corporate CEOs are headline news. Stock prices rise and fall at word of their hiring and firing. Business media debate their merits and defects as if individual leaders determined the health of the economy. Yet we know surprisingly little about how CEOs are selected... View Details
- July 2002 (Revised December 2002)
- Case
Phase Two: The Pharmaceutical Industry Responds to AIDS
By: Debora L. Spar
Describes how major pharmaceutical firms changed their strategy and pricing policies in the years 2000 to 2002 to respond to the growing AIDS epidemic in Africa. View Details
- July 2002 (Revised August 2014)
- Case
WellSpace Treatment Centers for Complementary and Alternative Medicine (A)
By: Regina E. Herzlinger, Jun HuangPu and Bing Lin
How should WellSpace, a venture capital-backed purveyor of alternative health services, expand? Although it was nearing breakeven in its first location, the right business model remained unclear. View Details
- July 2002
- Article
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
- January 2002
- Case
Price-Fixing Vignettes
By: Guhan Subramanian and Michelle Kalka
This case escribes the antitrust prosecutions in the United States and abroad of the international bulk vitamins cartel. Both the civil and criminal fines were historically high, and it was the first time the United States prosecuted foreign nationals for U.S. criminal... View Details
- August 2001 (Revised March 2008)
- Case
Helios Health (A)
By: Regina E. Herzlinger and Alfred Martin
Helios PC system provides personalized drug information to the patients in the doctor's waiting room. It has met with considerable consumer acceptance and a very high return for the drug companies that sponsor it. What price should it charge them for the service? View Details
- August 2001 (Revised February 2020)
- Case
Consumer-Driven Health Care: Medtronic's Health Insurance Options
By: Regina E. Herzlinger, John Hurwitch and Seth Bokser
Describes the variety of health insurance plans that this medical device company offers, including a high-deductible, consumer-driven health plan with a health reimbursement account that also enables health care providers to quote their own prices. Asks students to... View Details
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
- July 2001 (Revised August 2005)
- Case
Medicines Company, The
It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The... View Details
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
- 2001
- Chapter
Publicly Funded Science and the Productivity of the Pharmaceutical Industry
By: Rebecca Henderson and Ian Cockburn
U.S. taxpayers funded $14.8 billion of health related research last year, four times the amount that was spent in 1970 in real terms. In this paper we evaluate the impact of these huge expenditures on the technological performance of the pharmaceutical industry. While... View Details
- July 2000 (Revised November 2001)
- Case
Catalyst Medical Solutions
By: Amy C. Edmondson, Richard M.J. Bohmer and Naomi Atkins
Faced with a drop in the NASDAQ, four eHealth entrepreneurs must decide between two distribution strategies for their new company's technology. The team, comprised of three full-time resident physicians and an MBA, has developed software to enable electronic... View Details
- May 2000 (Revised January 2003)
- Case
Health Development Corporation
Health Development Corp. (HDC) owns and operates health clubs in the Greater Boston area. HDC engaged a local investment banker to explore a sale of the company. The most likely buyer views HDC's prior purchase of real estate as a negative. HDC's management is... View Details
Keywords: Cash Flow; Property; Business Exit or Shutdown; Valuation; Value; Decisions; Health Industry; Boston